Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on tтАж [+3126 chars]
No comments yet. Be the first to comment!
┬й 2026 Star News 1. рд╕рд░реНрд╡рд╛рдзрд┐рдХрд╛рд░ рд╕реБрд░рдХреНрд╖рд┐рддред рдЧреЛрдкрдиреАрдпрддрд╛ рдиреАрддрд┐ | рдирд┐рдпрдо рдФрд░ рд╢рд░реНрддреЗрдВ | рдЕрд╕реНрд╡реАрдХрд░рдг
ЁЯЗоЁЯЗ│ рднрд╛рд░рдд рдорд╛рддрд╛ рдХреА рдЬрдп ЁЯЗоЁЯЗ│